Tesaglitazar

Tesaglitazar
Systematic (IUPAC) name
	(2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl); ethoxy]phenyl]propanoic acid
Legal status
Legal status	Development terminated;
Identifiers
CAS Number	251565-85-2
ATC code	None
PubChem	CID 208901
ChemSpider	180999
UNII	6734037O3L
KEGG	D01274
ChEMBL	CHEMBL521632
Chemical data
Formula	C20H24O7S
Molar mass	408.46 g/mol
3D model (Jmol)	Interactive image
	SMILES CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O ;
	InChI InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1 ; Key:CXGTZJYQWSUFET-IBGZPJMESA-N ;
(what is this?) (verify)

Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.^[1]

The drug had completed several phase III clinical trials,^[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.^[3]

References[edit]

^ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
^ "GALIDA (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17. ^{[dead link]}
^ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2012-07-23.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.